The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials-Reference-Cited by-同舟云学术

The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials

Published:2017-03 Issue: Volume:74 Page:89-95
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Donia Marco,Kimper-Karl Marie Louise,Høyer Katrine Lundby,Bastholt Lars,Schmidt Henrik,Svane Inge Marie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Checkpoint blockade for the treatment of advanced melanoma;Callahan;Cancer Treat Res,2016

2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0: cancer incidence and MortalityWorldwide: IARC CancerBase No. 11. n.d. http://globocan.iarc.fr [Accessed 28 July 2014].

3. Statistic Denmark. Q12014 n.d.

4. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

5. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study;European Journal of Cancer;2024-07

2. Long‐term efficacy of neoadjuvant–adjuvant targeted therapy in borderline resectable stage IIIB–D and IV melanoma;Cancer;2024-06-06

3. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma;European Journal of Cancer;2024-05

4. The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting;Cancer Medicine;2024-03

5. Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study;Cancers;2024-02-07